Visualization of Eluvia Drug-Eluting Stent, from side close-up.
Three confident healthcare professionals in operating room, looking at screen.


Innovation meets
efficient drug transfer.

Eluvia DES is designed to meet the challenges of the SFA with outstanding flexibility and precise stent placement. Only Eluvia DES offers sustained drug release, with the world’s most proven polymer, to match the restenotic process of SFA.

A technology based on polymer designed for controlled release

Eluvia drug-eluting stent (DES) has the lowest drug dose1 (0.167 µg/mm2) delivered by the world’s most proven polymer. Built to ensure targeted delivery to the lesion while minimising downstream particulates and features the lowest systemic drug exposure for the patient among all peripheral paclitaxel-based technologies2.


Infographic of Eluvia drug eluting stent illustrating 92.1% patency at one year.

Downstream Impact

Eluvia’s polymer minimises downstream particulates and showed similar particulate loss compared to a bare metal stent3.

Illustration of Eluvia DES particulates vs bare metal stent illustration.

Eluvia DES Product Details

Eluvia matrics illustrating stent lengths

Triaxial Delivery System

Built for more precise and predictable stent placement.

Innova self-expanding nitinol stent system for Superficial Femoral Artery (SFA)

Background image of surgical area and healthcare providers' hands.

Explore DE Resources

Get physician perspectives, clinical data sheets and other resources about drug-eluting innovations.

Background image of healthcare providers' hands using medical equipment.

Stay Up to Date

Receive emails about the latest drug-eluting technology news, innovations and events in your area.

take the fight to pad